



PATENT
Attorney Docket No. OPHD-03282

GP/1646
12/14/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John A. Kink
Serial No.: 09/095,536
Filed: 06/10/98
Entitled: Prevention and Treatment of Sepsis

Group No.: 1646
Examiner: Hamud, F.

INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL

RECEIVED


DEC 09 1999

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231


Dated: December 3, 1999 By: 
Christopher J. Collins

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: December 3, 1999


Peter G. Carroll
Registration No. 32,837

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415/705-8410




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John A. Kink
Serial No.: 09/095,536
Filed: 06/10/98
Entitled: Prevention and Treatment of Sepsis

Group No.: 1646
Examiner: Hamud, F.

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
Dated: <u>December 3, 1999</u>	By:  Christopher J. Collins

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

Applicant has become aware of the following printed publications which may be material to the examination of this application:


- U.S. Patent No. 5,420,253 to Emery *et al.*; discloses a method for the purification of egg yolk immunoglobulins. A composition comprising anti-TNF and anti-IL-6 antibodies or its use in the treatment of sepsis, as claimed in the present invention, is not disclosed.
- Doherty *et al.*, "Evidence for IFN- γ as a Mediator of the Lethality of Endotoxin and Tumor Necrosis Factor- α ," *J. Immunology* 149(5):1666-1670 (1992); discloses INF-gama as a mediator of TNF-alpha induced septic shock. A

composition comprising anti-TNF and anti-IL-6 antibodies or its use in the treatment of sepsis, as claimed in the present invention, is not disclosed.

- Mantney *et al.*, "The role of cytokines in host responses to endotoxin," *Reviews in Medical Microbiology* 3(2):72-79 (1992); reviews the role of cytokines in host responses to gram-negative bacillary sepsis including the used of anti-TNK-alpha to protect mice passively challanged with a lethal dose of LPS. A composition comprising anti-TNF and anti-IL-6 antibodies or its use in the treatment of sepsis, as claimed in the present invention, is not disclosed; and
- Starnes *et al.*, "Anti-IL-6 Monoclonal Antibodies Protect Against Lethal Escherichia coli Infection and Lethal Tumor Necrosis Factor- α challenge in mice," *J. of Immun.* 145(12):4185-4191 (1990); discloses the use of anti-IL-6 monoclonal antibodies to pretreat mice subsequently challanged with *E. coli* or TNF-alpha. A composition comprising anti-TNF and anti-IL-6 antibodies or its use in the treatment of sepsis, as claimed in the present invention, is not disclosed.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: December 3, 1999



Peter G. Carroll
Registration No. 32,837

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
617/252-3353